Browse drugs

…L1 and B-hVEGFA MC38 syngeneic model, administration of 1 mg/kg AK112 significantly inhibited tumor growth. Although the initial comb…

… in increased ATP release and calreticulin exposure compared to cisplatin.Conclusions We show the syngeneic orthotopic model of TNBC is a…

…sion of the exhaustion markers TIM-3, PD-1, and LAG-3. Notably, TIM-4-L exposure on tumor cells representing hematologic and solid tumo…

…ector:Target ratio). Significant reduction in tumor burden with EP10 was also observed in A549 (p<0.0001, 2-way ANOVA) and 143B xeno…

…lamed signature, IFN-γ signatures, and tumor mutational burden. IMIREG’s utility was shown to be predictive, not prognostic. Mechanist…

… detectable, the animals were randomized into groups to receive Y111 CAR T or untransduced T cells via different routes of administr…

…ed HLA-A*03:01-restricted TCRs for the peptides gp100 17-25 and MAGE-A196-104 were isolated from peripheral blood after vaccination. Multiple…

…and high KI efficiency (24-42%), as measured by flow cytometry. TK-6302 DPs were highly enriched for memory cells, with ≥45% of cells e…

… both personalized and off-the-shelf immunotherapy applications.Bria-OTS+ represents a next-generation cancer vaccine that integrates cla…

…ce of tumor-reactive T cells. We demonstrate that dual ICB with anti-PD-1 and anti-CTLA-4 primes the tumor immune microenvironment to enh…

… The BaseTIL-03M trial demonstrates that combining TIL-ACT with ANV419 is feasible and well tolerated, with no dose-limiting toxicitie…

…r findings establish a novel ‘microbiota-immune’ paradigm where cordycepin potentiates CTLA-4 blockade through: (i) selective enrichment o…